18 June 2013
Keywords: new, data, repligen, rg2133, usa-based, released, positive
Article | 21 June 2004
USA-based Repligen has released positive findings from a Phase I, open-label trial of its RG2133, a prodrug of uridine. The ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
21 June 2004
17 June 2013
© 2013 thepharmaletter.com